• New 3.2 mm LSO crystals and industry’s fastest Time of Flight¹ help visualize small lesions more clearly and maximize efficiency
• New motion management features help improve delineation and quantification of small lesions, increasing confidence
The Food and Drug Administration (FDA) has cleared the Biograph Vision, a new positron emission tomography/computed tomography system from Siemens Healthineers that delivers a new level of precision in PET/CT imaging.
The Biograph Vision features new Optiso Ultra Dynamic Range (UDR) Detector Technology, which is based on silicon photomultipliers (SiPMs) rather than the photomultiplier tubes (PMTs) that have been the industry standard. This new system design enables Siemens Healthineers to reduce the detector’s lutetium oxyorthosilicate (LSO) crystal elements from 4 x 4 mm to 3.2 x 3.2 mm, resulting in higher spatial resolution. Utilizing these extremely small LSO crystals and covering 100 percent of the area of the scintillator array with SiPMs, the Biograph Vision is designed to deliver industry’s fastest time-of-flight (ToF), with a temporal resolution of just 249 picoseconds, as well as the highest effective sensitivity at 84 cps/kBq¹. For these reasons, the Biograph Vision helps to reduce scan time by a factor of 3.9 to improve patient throughput as well as reduce patient radiation exposure and tracer cost.
The Biograph Vision also has a large 78-cm bore that offers 24 percent more space than a 70-cm bore. This larger bore can reduce patient anxiety in addition to enabling easier positioning for radiotherapy (RT) devices or bariatric patients. The system fits into any room that houses a PET/CT scanner from the Biograph mCT family without the need for costly renovations.
Additionally, the Biograph Vision offers optional features to improve the quality of patient care. FlowMotion Multiparametric Suite, the industry’s first automated solution for whole-body parametric PET exams, provides not just the standard uptake volume (SUV), but also information regarding metabolic glucose rate and distribution volume. This information helps clinicians differentiate between non-metabolized and metabolized fluorodeoxyglucose (FDG) in the patient. OncoFreeze and CardioFreeze provide PET/CT images that are virtually free of motion in the same period of time as a regular whole-body scan, helping to improve lesion conspicuity, delineation, and quantification compared to images acquired without these features.
“The Biograph Vision represents a major leap in performance beyond any PET/CT system previously manufactured,” said Jim Williams, PhD, head of Siemens Healthineers Molecular Imaging. “With this system, we extend the boundaries of PET imaging and help our customers explore a new frontier in precision medicine.”
¹ Compared to competitive information available at time of publication and internal measurements. Data on file.
Contact for journalists
Phone: (484) 868-8346; Email: email@example.com
Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services.
In fiscal 2017, which ended on September 30, 2017, Siemens Healthineers generated revenue of €13.8 billion and profit of €2.5 billion and has about 48,000 employees worldwide. Further information is available at www.siemens-healthineers.com.